Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 499

1.

Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children.

Vesikari T, Karvonen AV, Majuri J, Zeng SQ, Pang XL, Kohberger R, Forrest BD, Hoshino Y, Chanock RM, Kapikian AZ.

J Infect Dis. 2006 Aug 1;194(3):370-6. Epub 2006 Jun 23.

PMID:
16826486
2.

Neonatal administration of rhesus rotavirus tetravalent vaccine.

Vesikari T, Karvonen A, Forrest BD, Hoshino Y, Chanock RM, Kapikian AZ.

Pediatr Infect Dis J. 2006 Feb;25(2):118-22.

PMID:
16462287
3.

Comparison of live and inactivated tick-borne encephalitis virus vaccines for safety, immunogenicity and efficacy in rhesus monkeys.

Rumyantsev AA, Chanock RM, Murphy BR, Pletnev AG.

Vaccine. 2006 Jan 12;24(2):133-43. Epub 2005 Aug 9.

PMID:
16115704
4.

A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception.

Kapikian AZ, Simonsen L, Vesikari T, Hoshino Y, Morens DM, Chanock RM, La Montagne JR, Murphy BR.

J Infect Dis. 2005 Sep 1;192 Suppl 1:S22-9. Review.

PMID:
16088801
5.

Transmission of acute infectious nonbacterial gastroenteritis to volunteers by oral administration of stool filtrates. 1971.

Dolin R, Blacklow NR, DuPont H, Formal S, Buscho RF, Kasel JA, Chames RP, Hornick R, Chanock RM.

J Infect Dis. 2004 Jun 1;189(11):2142-7, discussion 2139-41. No abstract available.

PMID:
15143483
6.

Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus.

Pletnev AG, Claire MS, Elkins R, Speicher J, Murphy BR, Chanock RM.

Virology. 2003 Sep 15;314(1):190-5.

7.

Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions.

Murphy BR, Morens DM, Simonsen L, Chanock RM, La Montagne JR, Kapikian AZ.

J Infect Dis. 2003 Apr 15;187(8):1301-8. Epub 2003 Apr 2. No abstract available.

PMID:
12696010
9.

Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.

Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, Thumar B, Men R, Lai CJ, Elkins WR, Chanock RM, Murphy BR, Whitehead SS.

Am J Trop Med Hyg. 2001 Nov;65(5):405-13.

PMID:
11716091
10.

Current research on respiratory viral infections: Third International Symposium.

Schmidt AC, Couch RB, Galasso GJ, Hayden FG, Mills J, Murphy BR, Chanock RM.

Antiviral Res. 2001 Jun;50(3):157-96. Review. No abstract available.

PMID:
11397506
11.

Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy.

Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE Jr, Boyce TG, Halburnt LL, Reed GW, Whitehead SS, Anderson EL, Wittek AE, Casey R, Eichelberger M, Thumar B, Randolph VB, Udem SA, Chanock RM, Murphy BR.

J Infect Dis. 2000 Nov;182(5):1331-42. Epub 2000 Sep 22.

PMID:
11010838
12.

Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults.

Gonzalez IM, Karron RA, Eichelberger M, Walsh EE, Delagarza VW, Bennett R, Chanock RM, Murphy BR, Clements-Mann ML, Falsey AR.

Vaccine. 2000 Mar 6;18(17):1763-72.

PMID:
10699324
13.

Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics.

Collins PL, Whitehead SS, Bukreyev A, Fearns R, Teng MN, Juhasz K, Chanock RM, Murphy BR.

Adv Virus Res. 1999;54:423-51. Review.

PMID:
10547682
14.

Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines.

Sakurai H, Williamson RA, Crowe JE, Beeler JA, Poignard P, Bastidas RB, Chanock RM, Burton DR.

J Virol. 1999 Apr;73(4):2956-62.

15.

Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein.

Crowe JE, Firestone CY, Crim R, Beeler JA, Coelingh KL, Barbas CF, Burton DR, Chanock RM, Murphy BR.

Virology. 1998 Dec 20;252(2):373-5.

16.

Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo.

Crowe JE Jr, Gilmour PS, Murphy BR, Chanock RM, Duan L, Pomerantz RJ, Pilkington GR.

J Infect Dis. 1998 Apr;177(4):1073-6.

PMID:
9534985
18.

Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children.

Kapikian AZ, Hoshino Y, Chanock RM, PĂ©rez-Schael I.

J Infect Dis. 1996 Sep;174 Suppl 1:S65-72. Review.

PMID:
8752293
20.

Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates.

Crowe JE Jr, Bui PT, Firestone CY, Connors M, Elkins WR, Chanock RM, Murphy BR.

J Infect Dis. 1996 Apr;173(4):829-39.

PMID:
8603960
21.

Reminiscences of Albert Sabin and his successful strategy for the development of the live oral poliovirus vaccine.

Chanock RM.

Proc Assoc Am Physicians. 1996 Mar;108(2):117-26. No abstract available.

PMID:
8705731
22.
25.
26.

Isolation and characterization of a chimpanzee monoclonal antibody to the G glycoprotein of human respiratory syncytial virus.

Crowe JE Jr, Cheung PY, Wallace EF, Chanock RM, Larrick JW, Murphy BR, Fry K.

Clin Diagn Lab Immunol. 1994 Nov;1(6):701-6.

27.
30.

An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines.

Murphy BR, Hall SL, Kulkarni AB, Crowe JE Jr, Collins PL, Connors M, Karron RA, Chanock RM.

Virus Res. 1994 Apr;32(1):13-36. Review.

PMID:
8030364
31.

Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice.

Crowe JE Jr, Murphy BR, Chanock RM, Williamson RA, Barbas CF 3rd, Burton DR.

Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1386-90.

32.

The remaining stocks of smallpox virus should be destroyed.

Mahy BW, Almond JW, Berns KI, Chanock RM, Lvov DK, Pettersson RF, Schatzmayr HG, Fenner F.

Science. 1993 Nov 19;262(5137):1223-4. No abstract available.

PMID:
8235651
34.
35.

Pathogenesis of adenovirus type 5 pneumonia in cotton rats (Sigmodon hispidus).

Prince GA, Porter DD, Jenson AB, Horswood RL, Chanock RM, Ginsberg HS.

J Virol. 1993 Jan;67(1):101-11.

36.

Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity.

Barbas CF 3rd, Crowe JE Jr, Cababa D, Jones TM, Zebedee SL, Murphy BR, Chanock RM, Burton DR.

Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10164-8.

37.

Coexpression of the simian immunodeficiency virus Env and Rev proteins by a recombinant human adenovirus host range mutant.

Cheng SM, Lee SG, Ronchetti-Blume M, Virk KP, Mizutani S, Eichberg JW, Davis A, Hung PP, Hirsch VM, Chanock RM, et al.

J Virol. 1992 Nov;66(11):6721-7.

38.

Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee.

Hsu KH, Lubeck MD, Davis AR, Bhat RA, Selling BH, Bhat BM, Mizutani S, Murphy BR, Collins PL, Chanock RM, et al.

J Infect Dis. 1992 Oct;166(4):769-75.

PMID:
1527411
39.

Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization.

Chanock RM, Parrott RH, Connors M, Collins PL, Murphy BR.

Pediatrics. 1992 Jul;90(1 Pt 2):137-43. Review. No abstract available.

PMID:
1603639
40.
41.

A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals.

Burton DR, Barbas CF 3rd, Persson MA, Koenig S, Chanock RM, Lerner RA.

Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10134-7.

42.

A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia.

Ginsberg HS, Moldawer LL, Sehgal PB, Redington M, Kilian PL, Chanock RM, Prince GA.

Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1651-5.

43.

Recent advances in development of a rotavirus vaccine for prevention of severe diarrheal illness of infants and young children.

Kapikian AZ, Flores J, Vesikari T, Ruuska T, Madore HP, Green KY, Gorziglia M, Hoshino Y, Chanock RM, Midthun K, et al.

Adv Exp Med Biol. 1991;310:255-64. Review. No abstract available.

PMID:
1667066
44.

Antigenic relationships among human rotaviruses as determined by outer capsid protein VP4.

Gorziglia M, Larralde G, Kapikian AZ, Chanock RM.

Proc Natl Acad Sci U S A. 1990 Sep;87(18):7155-9.

45.

Role of early genes in pathogenesis of adenovirus pneumonia.

Ginsberg HS, Horswood RL, Chanock RM, Prince GA.

Proc Natl Acad Sci U S A. 1990 Aug;87(16):6191-5. Erratum in: Proc Natl Acad Sci U S A 1991 Jan 15;88(2):681.

46.
47.

Mechanism of antibody-mediated viral clearance in immunotherapy of respiratory syncytial virus infection of cotton rats.

Prince GA, Hemming VG, Horswood RL, Baron PA, Murphy BR, Chanock RM.

J Virol. 1990 Jun;64(6):3091-2.

48.

Control of pediatric viral diseases: past successes and future prospects.

Chanock RM.

Pediatr Res. 1990 Jun;27(6 Suppl):S39-43. Review. No abstract available.

PMID:
2113272
49.

Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus.

Collins PL, Purcell RH, London WT, Lawrence LA, Chanock RM, Murphy BR.

Vaccine. 1990 Apr;8(2):164-8.

PMID:
2336876

Supplemental Content

Loading ...
Support Center